Mutations and polymorphisms in the gene encoding factor H (CFH) have been associated with atypical Hemolytic Uremic Syndrome (aHUS), Dense Deposit Disease (DDD) and Age-related Macular Degeneration (AMD). Experimental evidence supports that many of these CFH genetic variations disrupt the regulatory role of factor H (FH), sustaining the concept that dysregulation of complement is a unifying pathogenic feature of these disorders. Evidence of a causal relationship with the disease is, however, not available for all CFH genetic variations found in patients, which is a potential cause of misinterpretations with important consequences for the patients and their relatives. I890 and L1007 are two of such CFH genetic variations. They have repeatedly been reported associated with aHUS and are also found in DDD and AMD patients. Here we report an extensive genetic and functional analysis of these CFH variants. Our results indicate that I890 and L1007 segregate together as part of a distinct and relatively infrequent CFH haplotype in Caucasians. Extensive analysis of the purified S890/V1007 (control) and I890/L1007 (disease-associated) FH protein variants failed to provide evidence that these amino acid substitutions have functional implications. These data, the presence of the I890 and L1007 variants in healthy individuals and their high frequency in Sub-Saharan African and African American populations strongly suggest that I890 and L1007 are FH rare polymorphisms unrelated with disease.
INTRODUCTION

Complement factor H (FH) is the main regulator of the alternative pathway (AP)
of the complement system. FH exerts this regulatory activity in three different ways: it binds to C3b, competing with factor B (FB) in the assembly of the AP C3-proconvertase complex (C3bB); it accelerates the decay of the AP C3-convertase (C3bBb); and acts as cofactor of factor I (FI) in the proteolytic inactivation of C3b [1] [2] [3] .
FH regulates complement activation both in fluid phase and on cellular surfaces [4] [5] [6] , preserving complement homeostasis and preventing uncontrolled C3b deposition and host tissue damage.
FH is a relative abundant plasma protein that is secreted as a single-chain glycoprotein of 155 KD composed of 20 homologous domains of 60 amino acids 7 , named short consensus repeats (SCR). FH concentration in plasma is highly variable, ranging from 116 to 562 µg/ml 8 . Different interaction sites for C3b and polyanions have been identified along the 20 SCR of FH. The SCR 1-4 region is the unique C3b binding site capable to act as cofactor for FI in the cleavage of C3b and to accelerate the decay of AP C3-convertase 9 . Similarly, the C3b and polyanion binding site at SCR 19-being instrumental to understand the molecular basis underlying each of these pathologies.
In aHUS, a thrombotic microangiopathy characterized by thrombocytopenia, haemolytic anemia and acute renal failure, and where endothelial cell injury appears to be the primary pathogenic event, the most prevalent genetic alterations in the CFH gene are missense mutations that alter the C3b-and polyanion-binding site at the C-terminus of FH. These mutations rarely result in hypocomplementemia or decreased FH plasma levels [13] [14] [15] [16] . Functional studies have demonstrated that these aHUS-associated FH molecules present normal regulatory activity in plasma but a limited capacity to protect cells from complement lysis [17] [18] [19] [20] . This functional alteration is clearly distinct from the lack of complement regulation in plasma, leading to complete C3 consumption and severe hypocomplementemia that characterizes DDD patients.
DDD is a very rare form of glomerulonephritis with isolated C3 deposits characterized by the presence of dense deposits within the glomerular basement membrane (GBM) 21 . DDD is associated with complement abnormalities that lead to persistent reduction of C3 serum levels and to intense deposition of degradation products of C3 in the GBM. Among the different factors associated with these complement abnormalities are mutations in the CFH gene. These CFH mutations result in truncations or amino acid substitutions that impair secretion of FH into circulation or that eliminate the complement regulatory activities located at the N-terminus of FH 22-24 .
Thus, CFH mutations that decrease FH in plasma, or eliminate its complement regulatory activity, lead to unrestricted activation of complement in plasma, causing damage to glomerular cells and deposition of complement products in the GBM.
Age-related macular degeneration (AMD), the most common cause of blindness in the elderly in developed countries, is characterized by drusen, lipoproteinaceous deposits localized between the retinal pigment epithelium (RPE) and Bruch´s membrane, that lead to an extensive atrophy of the RPE and overlaying photoreceptor cells (geographic atrophy, GA) or aberrant choroidal neovascularization (CNV) under the macular area. AMD and DDD share pathological similarities with accumulation of complement-containing debris within the eye and kidney respectively. Indeed, AMDlike pathology is well-recognized in patients with DDD 25 . The identification of CFH as a major susceptibility locus for AMD and the characterization of multiple genetic variants in the CFH genomic regions conferring risk or protection to AMD indicate that the complement system plays a significant role in AMD pathogenesis [26] [27] [28] [29] [30] . However, CFH association data showed no overlapping between CFH at-risk polymorphisms for aHUS and AMD 20 .
The peculiar genotype-phenotype correlation between specific CFH genetic variations and a particular disease contrast with the situation of the CFH I890 and L1007 variations (in SCR 15 and SCR 17, respectively) that have been repeatedly reported associated with aHUS and are also found in DDD and AMD patients 29, 31-33 .
To characterize the functional consequences of these CFH genetic variations we have purified the different FH protein variants to homogeneity from the plasma of appropriate carriers and tested their capacity to bind to surface-bound C3b, analyzed their cofactor activity in the FI-mediated inactivation of fluid phase C3b and performed FH-dependent hemolytic assays. None of these assays showed functional alterations in the regulatory activity of the FH, which strongly suggest that they are rare FH polymorphisms without functional consequences. heterozygote donors ( Figure 1 ). After quantification by ELISA, the purified proteins, S890/V1007, I890/L1007 and I890/L1007/L1191/A1197, were tested functionally in a number of different assays.
RESULTS
Sequencing analyses of the
To test whether the I890/L1007 amino acid changes affect the cofactor activity for the FI-mediated proteolysis of C3b, S890/V1007 and I890/L1007 FH variants were mixed with C3b and incubated in the presence of FI at 37ºC. After densitometric analysis of coomassie stained gels, the ratio between α´chain/βchain of C3b was used to calculate the percentage of C3b cleavage. As illustrated, no differences in the cofactor activities between FH variants S890/V1007 and I890/L1007 (Figure 2A ,B) or between S890/V1007 and I890/L1007/L1191/A1197 ( Figure 2A ,B,C) were appreciated, indicating that these amino acid substitutions do not have a significant effect on the cofactor activity of FH. As a control that our assays have appropriate sensitivity to detect small functional alterations we have included in these experiments the V62 and I62 FH polymorphic variants previously, which shown to present slightly differences in their FI cofactor activities 36 ( Figure 2D )
To explore the effect of the I890/L1007 amino acid changes in the interaction with C3b we performed a C3b binding plate assay. Purified C3b was immobilized on microtiter plates and identical quantities of the I890/L1007 and S890/V1007 FH variants were added and allowed to interact for two hours at 37°C. FH bound to C3b was detected using the Ox24 monoclonal antibody. FH was quantified in parallel in the same ELISA experiment. Our results show that the binding to C3b of the purified FH protein I890/L1007 was undistinguishable from that of the control FH S890/V1007
( Figure 3A ). These results indicate that the amino acid changes in the SCR 15 and 17 do not alter the capacity of FH to bind C3b. We also used in these experiments the V62 and I62 FH polymorphic variants as it has also been shown previously that they present slight differences in their C3b-binding capacity 36 ( Figure 3B ).
To investigate the potential effect of the I890 and L1007 amino acid changes in the regulatory activity of FH on cell surfaces, the S890/V1007 and I890/L1007 FH variants were tested in a FH-dependent hemolytic assay developed in our laboratory. In these assays a human serum carrying a well-characterized CFH mutation that alters the . In addition, S890I and V1007L were described as rare polymorphisms associated with AMD 29 .
The peculiar concurrence of both S890I and V1007L amino acid substitutions in all these cases is explained by the segregation analysis performed here in two aHUS pedigrees that revealed that these two amino acid changes segregate together with a unique CFH haplotype characterized by a specific combination of SNPs ( 
Proteins
FH allele carrying the mutations I890 and L1007 was isolated from fresh plasma of aHUS patient H54 and a relative of the aHUS patient H142. We used a CNBractivated sepharose 4B (GE healthcare) column coupled with the monoclonal antibody MBI-7 that exclusively recognizes the FH H402 protein variant 35 . Fractions containing FH were collected, concentrated and applied to a gel-filtration column (Superose 6, GE Healthcare). Fractions containing the FH were pooled and purity of final preparations was confirmed in SDS-PAGE coomassie stained gels (Figure 1 ). C3 was purified by affinity chromatography and gel filtration as described previously 43 . C3b was generated by limited digestion with trypsin and re-purified by gel filtration as described above.
C3b was obtained without any detectable contaminants or aggregates. Factor I was purchased from Comptech (Tyler, TX). Concentration of sample proteins was assessed using absorbance at 280 nm and molarities were calculated using an extinction coefficient for CFH of 1.95 35 and for C3 of 0.98 (Protean Software, DNAStar).
Cofactor activity for FI-mediated proteolysis of fluid phase C3b
The fluid-phase cofactor activity of FH was determined in a C3b proteolysis assay using purified proteins. In brief, C3b, FH and FI were mixed in 10 mM Hepes pH 7.5, 150 mM NaCl, 0.02% Tween 20 at final concentrations of 50 μg/ml, 4 μg/ml and 2.5 μg/ml, respectively. Mixtures were incubated at 37ºC during 10 minutes. In another set of assays, samples were collected at 2.5, 5, 7.5 and 10 minutes of incubation. The reactions were stopped by the addition of 3μl of SDS sample buffer (2% SDS, 62.5 mM Tris, 10% Glycerol, 0.75% Bromophenol Blue). Samples were analyzed in 10% SDS-PAGE under reducing conditions. Gels were stained with Coomassie brilliant blue R-250 (BioRad) and proteolysis of C3b determined by measuring the cleavage of the α'chain using a GS-800 calibrated densitometer (BioRad) and the MultiGauge software package (Fujifilm). The C3b βchain was used as an internal control to normalize the amount of protein added between samples. Percentage of cleavage was determined by the ratio between α´chain/βchain of C3b and setting as 0% of proteolysis by using a control FH in the absence of FI.
ELISA C3b-binding assay
The binding of FH variants to surface-bound C3b was determined by ELISA method. 96-well polystyrene microtiter plates were coated with C3b (2.5 μg/ml) in coupling buffer (0.1 M NaHCO 3 pH 9.5) overnight at 4ºC. The plate was blocked with washing buffer (20 mM Tris, 150 mM NaCl and 0.1% Tween 20) with 1% Bovine Serum Albumin for 1 hour at room temperature (RT). After washing, serial dilutions of FH variants (starting dilution was 2.5μg/ml) were added and incubated with surfacebound C3b for 2 hours at 37ºC. After washing, the plate was incubated with anti-FH monoclonal antibody Ox24 for 1 hour at RT, and then with a secondary antibody coupled with horseradish peroxidase (DAKO). Colour reaction was developed with ophenylene-diamine (DAKO) and absorbance measured at 492 nm. FH preparations used in the ligand assay were quantified in duplicate in the same ELISA plate using immobilised polyclonal anti-FH antibody to capture FH followed by the Ox24 and secondary antibodies to measure the amount of FH. Concentrations of FH were calculated from curves obtained using purified standard samples.
Factor H-dependent hemolytic assay
The capacity of FH to regulate the activity of the AP on cellular surfaces was assessed with a hemolytic assay using sheep erythrocytes and a serum carrying a well- were read at 414 nm. FH variants I890/L1007 and I890/L1007/L1191/A1197 were compared to the same control FH variant, S890/V1007, in two independent assays. S∆FH without added FH was taken as 100% of lysis and serum diluted in AP buffer plus 20 mM EDTA were used as blank for spontaneous lysis.
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